Toralizumab  (Synonyms: 托拉珠单抗; IDEC-131; Anti-Human CD40 ligand Recombinant Antibody)

Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab is an immunosuppressive agent. Toralizumab can lead to increased thrombosis. Toralizumab can be studied in research for diseases such as multiple sclerosis, systemic lupus erythematosus (SLE), and Crohn’s disease^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Toralizumab 在体外具有促血栓形成特性，这种特性由可结晶片段 (Fc)-γ 受体 IIa (FcγRIIa) 依赖的血小板活化介导，而血小板活化由抗 CD154 抗体交联可溶性 CD154 形成的高级免疫复合物触发^[4]。
Toralizumab (Compound IDEC-131) (0-200 mcg/mL) 在 MLR 中单独使用时可轻度降低淋巴细胞增殖反应，且这种降低不具有剂量依赖性^[5]。
Toralizumab 可阻断 HEC 与 D1.1 细胞共培养诱导的 CD62E 表达^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Toralizumab (Compound IDEC-131) (15-20 mg/kg/剂，静脉注射，第 0、1、3、7 天，然后每周一次，共 8 周) 可使未经治疗的猴子的生存期略长于未治疗的猴子^[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

959  [NCBI]

P29965

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.66 kDa

托拉珠单抗; IDEC-131; Anti-Human CD40 ligand Recombinant Antibody

252662-47-8

液体

Colorless to light yellow

托拉珠单抗； 托利珠单抗

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized CD40L/CD154/TRAP Protein, Human (His, HY-P72907) can bind Toralizumab. The EC₅₀ for this effect is 5.068 ng/mL.

• [1]. Camilo E Fadul, et al. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 Oct 15;8(6):e1096.  [Content Brief]

  [2]. Kenneth C Kalunian, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec;46(12):3251-8.  [Content Brief]

  [3]. Murphy, G., & Isenberg, D. A. (2019). New therapies for systemic lupus erythematosus - past imperfect, future tense. Nature reviews. Rheumatology, 15(7), 403-412.  [Content Brief]

  [4]. Lassiter, G., et al., (2023). TNX-1500, a crystallizable fragment-modified anti-CD154 antibody, prolongs nonhuman primate renal allograft survival. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 23(8), 1171-1181.  [Content Brief]

  [5]. Xu, H., et al., (2003). Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. Journal of immunology (Baltimore, Md.: 1950), 170(5), 2776-2782.  [Content Brief]